Background: Hepatocellular carcinoma (HCC) is increasing in incidence and treatment is often unsuccessful. Thus, prevention in high-risk patients with established cirrhosis has been proposed as an alt
Data are means ± SEM. *P<0.05 and ***P<0.001 DKO compared with C57BL/6 J mice; $$P<0.01 and $$$P<0.001 PPAR agonist-treated compared with placebo-treated DKO mice; £P<0.05 and £££P<0.001 rosiglitazone
